The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 21, 2021

Filed:

Oct. 02, 2017
Applicants:

The Trustees of the University of Pennsylvania, Philadelphia, PA (US);

The Regents of the University of California, Oakland, CA (US);

Inventors:

Vladimir Muzykantov, Bryn Athyn, PA (US);

Jacob Brenner, Princeton Junction, NY (US);

Jacob Myerson, Clayton, MO (US);

Daniel Pan, Philadelphia, PA (US);

Samir Suresh Mitragotri, Lexington, MA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 9/00 (2006.01); A61K 47/69 (2017.01); A61K 47/61 (2017.01); A61K 47/64 (2017.01); A61K 38/18 (2006.01); A61K 51/12 (2006.01); A61K 49/00 (2006.01); A61K 31/137 (2006.01); A61K 31/573 (2006.01); A61K 47/68 (2017.01);
U.S. Cl.
CPC ...
A61K 47/6901 (2017.08); A61K 31/137 (2013.01); A61K 31/573 (2013.01); A61K 38/18 (2013.01); A61K 47/61 (2017.08); A61K 47/64 (2017.08); A61K 47/643 (2017.08); A61K 47/6843 (2017.08); A61K 47/6849 (2017.08); A61K 47/6903 (2017.08); A61K 47/6911 (2017.08); A61K 47/6913 (2017.08); A61K 47/6935 (2017.08); A61K 49/0073 (2013.01); A61K 49/0097 (2013.01); A61K 51/1203 (2013.01); A61K 51/1213 (2013.01); A61K 51/1244 (2013.01);
Abstract

Compositions comprising a red blood cell (RBC) having non-toxically coupled thereto a nanoparticle having a low shear modulus or low Young's modulus of less than 10 MPa and containing a drug are provided. In one embodiment, the nanoparticles are optionally coated with protein. In another embodiment, the nanoparticle has no cell-specific targeting moiety or tissue-specific targeting moiety or organ-specific targeting moiety associated therewith. Methods of delivering selected drugs to target organs use these compositions both in vivo and ex vivo treatment of disease and for imaging.


Find Patent Forward Citations

Loading…